Cytosorbents Corporation
CTSO
$0.8911
-$0.022-2.41%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 10.20% | 33.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.20% | 33.79% | |||
| Cost of Revenue | 11.25% | 1,116.38% | |||
| Gross Profit | 9.77% | -8.32% | |||
| SG&A Expenses | 8.72% | -14.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.90% | 15.92% | |||
| Operating Income | 7.00% | 10.82% | |||
| Income Before Tax | 231.70% | 84.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 231.70% | 81.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 231.70% | 81.25% | |||
| EBIT | 7.00% | 10.82% | |||
| EBITDA | 8.76% | 11.35% | |||
| EPS Basic | 227.98% | 83.14% | |||
| Normalized Basic EPS | 227.63% | 86.55% | |||
| EPS Diluted | 223.46% | 83.14% | |||
| Normalized Diluted EPS | 219.08% | 86.55% | |||
| Average Basic Shares Outstanding | 3.09% | 11.00% | |||
| Average Diluted Shares Outstanding | 10.59% | 11.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||